Tag:
Bayer Healthcare
Latest Headlines
Latest Headlines
Bayer details positive PhIII data on cancer blockbuster hopeful regorafenib
Bayer HealthCare took another step toward a planned marketing application for the cancer drug regorafenib today as it unveiled the late-stage colorectal cancer data that it plans to take to
Ventana, Bayer to collaborate on companion Dx for cancer
Another week, another big personalized medicine partnership announcement from Ventana Medical Systems . This time, the Roche unit said it will be working with Bayer Pharma on a molecular companion
Onyx Pharma shares soar on report of its hunt for options, acquirers
A report about Onyx Pharmaceuticals' ( $ONXX ) search for business alternatives such as a company sale has generated buzz in the biotech world. Bloomberg reported Monday afternoon that the South San
FDA pins approval on Regeneron eye drug Eylea
Regeneron ( $REGN ) is wrapping up the week with a big victory. U.S. regulators have given market approval to the Tarrytown, NY-based company's Eylea for treating a neurovascular form of wet
Bayer settles Onyx spat with $160M payout, sales rights and royalties
Longtime partners Onyx Pharmaceuticals and Bayer have patched up a long-running dispute over who owns the rights to a Phase III cancer drug that bears a close resemblance to the blockbuster Nexavar
What's the best strategy for working with FDA regulators?
Today FDA staffers published an even-handed evaluation of VEGF Trap Eye ( aflibercept ). As Bloomberg reports, the drug helps prevent vision loss just as well as a rival treatment on the market. And it
Algeta shares spike on promising prostate cancer drug data
Shares of Norway's Algeta spiked 36 percent this morning after the biotech's partner Bayer unveiled promising data on their castration-resistant prostate cancer treatment Alpharadin (radium-223
Medtronic, Bayer Healthcare extend diabetes alliance
Medtronic and Bayer HealthCare have expanded their alliance to include the U.S. The companies will work exclusively to develop next generation diabetes management solutions for patients. The
Bayer CEO sketches the perfect takeover target
Bayer CEO Marijn Dekkers recently sat down with Bloomberg and dropped a few tantalizing hints about his idea of the ideal takeover target. While Dekkers declined to speculate on a possible short list
Bayer looks to JVs, not buys, for Indian growth
After Bayer set out disappointing earnings targets for the next two years, Bayer CFO Werner Baumann told Reuters one of his strategies for fighting back--without betting the farm in the process. Like
